Clinical Efficacy And Safety Of Concurrent Chemoradiotherapy Combined With Endostatin Targeted Therapy For The Treatment Recurrent Cervical

Objective: To study the clinical efficacy and safety of concurrent chemoradiotherapy combined with Endostatin targeted therapy for the treatment of recurrent cervical cancer,and then to find more effective methods to improve the efficacy for patients with recurrent cervical cancer,and prolong their survival period.Methods: The clinical data of patients with recurrent cervical cancer admitted to Qinghai Red Cross hospital Hospital from November 2014 to September 2019 were collected and divided into the Endostatin group and the control group according to the treatment methods.The control group consisted of 20 patients with concurrent chemoradiotherapy alone,and there were 24 patients with concurrent chemoradiotherapy combined with Endu therapy in Endu group.The clinical data of patients in two groups were analyzed.Results: The complete response rate(CR)of patients in the control group and Endostatin group were 15.0% and 45.8%,respectively,there were statistical differences(P<0.05).The total disease response rate(complete response(CR)+partial response(PR))of the patients in the control group and Endostatin group were 50.0% and 79.2%,respectively,the difference was statistically significant(p <0.05);the severity of bone marrow suppression and liver and kidney function damage of patients in the control group was higher than that in the Endostatin group,and the difference was statistically significant(P < 0.05);There were no statistically significant differences in gastrointestinal response and quality of life scores(P> 0.05)between the two groups;the median overall survival(OS)of patients in the control group and Endostatin group were 13.0 months and 20.0 months,respectively,and the median progression-free survival(PFS)were 21.0 months and 23.0 months,respectively,with no significant difference(P>0.05).Conclusion: Compared with chemoradiotherapy alone,Endu combined with concurrent chemoradiotherapy in the treatment of recurrent cervical cancer could increase the short-term efficacy(complete response rate,total disease response rate),while the long-term efficacy(overall survival,progression-free survival)can not be increased.The adverse reactions did not increase,the safety was good.